Cargando…

Establishment of immunoassay for detecting HPV16 E6 and E7 RNA

Cervical carcinoma is the most prevalent malignancy second only to breast cancer among women worldwide. Since more than 99% of cervical cancers are caused by human papilloma virus (HPV), measurement of HPV (HPV test) was commonly used in screening risk and/or early stage of cervical cancer as well a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Sen, Qian, Steven Y., Zhang, Yang, Wu, Wenlei, Lu, Gensheng, Lu, Yan, Feng, Xiujing, Li, Li, Shen, Pingping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558577/ https://www.ncbi.nlm.nih.gov/pubmed/26333509 http://dx.doi.org/10.1038/srep13686

Ejemplares similares

Development and validation of a multiplex immunoassay for the simultaneous quantification of type-specific IgG antibodies to E6/E7 oncoproteins of HPV16 and HPV18
por: Layman, Hans, et al.
Publicado: (2020)

Intrabodies targeting human papillomavirus 16 E6 and E7 oncoproteins for therapy of established HPV-associated tumors
por: Paolini, Francesca, et al.
Publicado: (2021)

Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancers
por: Chang, J T-C, et al.
Publicado: (2010)

HPV16 E6 upregulates Aurora A expression
por: Guo, Yi, et al.
Publicado: (2016)

E6/E7 and E6(*) From HPV16 and HPV18 Upregulate IL-6 Expression Independently of p53 in Keratinocytes
por: Artaza-Irigaray, Cristina, et al.
Publicado: (2019)

Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100
por: Morrow, Matthew P, et al.
Publicado: (2016)

A Non-oncogenic HPV 16 E6/E7 Vaccine Enhances Treatment of HPV Expressing Tumors
por: Wieking, Bryant G., et al.
Publicado: (2012)

Fusion of CTLA-4 with HPV16 E7 and E6 Enhanced the Potency of Therapeutic HPV DNA Vaccine
por: Gan, Lili, et al.
Publicado: (2014)

KSHV co-infection down-regulates HPV16 E6 and E7 from cervical cancer cells
por: Dai, Lu, et al.
Publicado: (2017)

Gene silencing of HPV16 E6/E7 induced by promoter-targeting siRNA in SiHa cells
por: Hong, D, et al.
Publicado: (2009)

Diversity of cervicovaginal human papillomavirus (HPV) genotypes and naturally occurring E6/E7 DNA polymorphisms of HPV-16 in Ghana
por: Kaba, Gladys, et al.
Publicado: (2023)

HPV16 E6/E7 -based mRNA vaccine is therapeutic in mice bearing aggressive HPV-positive lesions
por: Zhou, Kun, et al.
Publicado: (2023)

Construction and detection of the tissue-specific pINV-HPV16 E6/7 vector
por: GAO, HUI, et al.
Publicado: (2015)

Association of cervical carcinogenesis risk with HPV16 E6 and E7 variants in the Taizhou area, China
por: Dai, Mei-Zhen, et al.
Publicado: (2021)

The combined HPV16-E2/E6/E7 T cell response in oropharyngeal cancer predicts superior survival
por: Santegoets, Saskia J., et al.
Publicado: (2023)

Editorial expression of concern: Cdc6 expression is induced by HPV16 E6 and E7 oncogenes and represses E-cadherin expression
por: Faghihloo, E., et al.
Publicado: (2020)

Disruption of HPV16-E7 by CRISPR/Cas System Induces Apoptosis and Growth Inhibition in HPV16 Positive Human Cervical Cancer Cells
por: Hu, Zheng, et al.
Publicado: (2014)

Human papillomavirus 16 (HPV 16) E6 but not E7 inhibits the antitumor activity of LKB1 in lung cancer cells by downregulating the expression of KIF7
por: Hu, Yue, et al.
Publicado: (2020)

Identification of variants and therapeutic epitopes in HPV-33/HPV-58 E6 and E7 in Southwest China
por: He, Jiaoyu, et al.
Publicado: (2019)

HPV 16 E7 alters translesion synthesis signaling
por: Wendel, Sebastian O., et al.
Publicado: (2022)

Identification of novel HLA-A*11:01-restricted HPV16 E6/E7 epitopes and T-cell receptors for HPV-related cancer immunotherapy
por: Xiong, Chengjie, et al.
Publicado: (2022)

Characterization of Epithelial Progenitors in Normal Human Palatine Tonsils and Their HPV16 E6/E7-Induced Perturbation
por: Kang, Sung Yoon Catherine, et al.
Publicado: (2015)

Design, Immune Responses and Anti-Tumor Potential of an HPV16 E6E7 Multi-Epitope Vaccine
por: de Oliveira, Liliane Maria Fernandes, et al.
Publicado: (2015)

Cervical Cancer Development: Implications of HPV16 E6E7-NFX1-123 Regulated Genes
por: Quist, Kevin M., et al.
Publicado: (2021)

Differential localization of HPV16 E6 splice products with E6-associated protein
por: Vaeteewoottacharn, Kulthida, et al.
Publicado: (2005)

Development and validation of a multiplex qPCR assay for detection and relative quantification of HPV16 and HPV18 E6 and E7 oncogenes
por: Bordigoni, Alexia, et al.
Publicado: (2021)

Control of Spontaneous HPV16 E6/E7 Expressing Oral Cancer in HLA-A2 (AAD) Transgenic Mice with Therapeutic HPV DNA Vaccine
por: Tseng, Ssu-Hsueh, et al.
Publicado: (2021)

FLT3L and granulocyte macrophage colony-stimulating factor enhance the anti-tumor and immune effects of an HPV16 E6/E7 vaccine
por: Ding, Zhenzhen, et al.
Publicado: (2019)

Generation of affibody molecules specific for HPV16 E7 recognition
por: Xue, Xiangyang, et al.
Publicado: (2016)

Prognostic and diagnostic validity of p16/Ki-67, HPV E6/E7 mRNA, and HPV DNA in women with ASCUS: a follow-up study
por: Ren, Chenchen, et al.
Publicado: (2019)

Nanog, in Cooperation with AP1, Increases the Expression of E6/E7 Oncogenes from HPV Types 16/18
por: Díaz-Tejeda, Yakelin, et al.
Publicado: (2021)

HPV16-E6/E7 Oncogene Mutation and p53 Expression among Indonesian Women with Cervical Cancer
por: Mahendra, I Nyoman Bayu, et al.
Publicado: (2022)

Realgar, a traditional Chinese medicine, induces apoptosis of HPV16-positive cervical cells through a HPV16 E7-related pathway
por: Ding, Wencheng, et al.
Publicado: (2018)

A novel HPV16 E7-affitoxin for targeted therapy of HPV16-induced human cervical cancer
por: Jiang, Pengfei, et al.
Publicado: (2018)

Sequential Cisplatin Therapy and Vaccination with HPV16 E6E7L2 Fusion Protein in Saponin Adjuvant GPI-0100 for the Treatment of a Model HPV16+ Cancer
por: Peng, Shiwen, et al.
Publicado: (2015)

Short half‐life of HPV16 E6 and E7 mRNAs sensitizes HPV16‐positive tonsillar cancer cell line HN26 to DNA‐damaging drugs
por: Wu, Chengjun, et al.
Publicado: (2018)

Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody
por: Peng, Shiwen, et al.
Publicado: (2021)

Effects of HPV16 E6 protein on Daxx-induced apoptosis in C33A cells
por: Tang, Shuangyang, et al.
Publicado: (2020)

Phylogeny and polymorphism in the E6 and E7 of human papillomavirus: alpha-9 (HPV16, 31, 33, 52, 58), alpha-5 (HPV51), alpha-6 (HPV53, 66), alpha-7 (HPV18, 39, 59, 68) and alpha-10 (HPV6, 44) in women from Shanghai
por: Zhao, Junwei, et al.
Publicado: (2019)

Increased Growth of a Newly Established Mouse Epithelial Cell Line Transformed with HPV-16 E7 in Diabetic Mice
por: He, Lan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_51p4srq0vb38851od3cj8dnd0u